Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

In the field of nanotherapeutics, gaining cellular entry into the cytoplasm of the target cell
continues to be an ultimate challenge. There are many physicochemical factors such as …

Engineered antibodies now represent over 30% of biopharmaceuticals in clinical trials, as
highlighted by recent approvals from the US Food and Drug Administration. Recombinant …

Bivalent ligands are increasingly important therapeutic agents. Although the naturally
occurring antibodies are predominant, it is becoming more common to combine different …

Active targeting in cancer nanomedicine, for improved delivery of agents and diagnose, has
been reviewed as a successful way for facilitating active uptake of theranostic agents by the …

Network and systems biology offer a novel way of approaching drug discovery by
developing models that consider the global physiological environment of protein targets …

With almost 20 million new cases per year, cancer constitutes one of the most important
challenges for public health systems. Unlike traditional chemotherapy, targeted anti-cancer …

The development of a number of different solid tumours is associated with over-expression
of ErbB1, or the epidermal growth factor receptor (EGFR), and this over-expression is often …

Summation Many factors contribute to successful tumor targeting by antibodies. Besides
properties of the tumor tissue and general antibody pharmacology, a relationship exists …

Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are
currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody …